Shanghai Synergy Pharmaceutical Sciences Co. Ltd. and Zhejiang Huahai Pharmaceutical Group Co. Ltd. have patented C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of cancer, autoimmune diseases and inflammatory disorders.

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have synthesized salts of complement factor B (CFB) inhibitors reported to be useful for the treatment of allergy, asthma, age-related macular degeneration, inflammatory disorders, stroke, Parkinson’s, Crohn’s diseases and hepatic fibrosis, among others.

A joint Korea Research Institute of Chemical Technology and Novartis AG patent describes antiviral 1,3-di-oxo-indene compounds reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, diabetes, hepatitis A, viral infection, myocarditis, myositis and pancreatitis, among others.

Aeovian Pharmaceuticals Inc. has prepared tricyclic fused imidazole compounds acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of neurodegeneration, inflammation, fibrosis, systemic scleroderma and more.

Gilead Sciences Inc. has synthesized 4-aminopyrrolo[2,1-F][1,2,4]triazine C-nucleoside analogues acting as prodrugs of GS-441524 and reported to be useful for the treatment of viral infections.

Beijing Innovare Pharma Tech Co. Ltd. has reported heterocyclic molecular glue degrader compounds acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers.

Arkuda Therapeutics Inc. has patented new fused tricyclic mucolipin-1 (MCOLN1; TRPML1) blockers reported to be useful for the treatment of cancer, liver diseases, amyotrophic lateral sclerosis, cardiovascular disorders, frontotemporal dementia, Alzheimer’s, Huntington’s and Parkinson’s disease.

Several recent Imhotex Ltd. patents describe novel analogues of muramyl dipeptide (MDP), desmuramylpeptides (DMPs), acting as nucleotide-binding oligomerization domain-containing protein 2 (NOD2) activators potentially useful for the treatment of Crohn’s disease.

Verge Analytics Inc. (dba Verge Genomics) has prepared and tested new hydrazone and pyrazole 3H-imidazo(4,5-b)pyridine compounds acting as 1-phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) inhibitors.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented oxazolo[4,5-B]pyrazine and oxazolo[4,5-B]pyridine derivatives acting as NLRP3 inflammasome inhibitors and reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease and cardiovascular disorders.